Estija - estų - Ravimiamet

medochemie limited - entakapoon - õhukese polümeerikattega tablett - 200mg 500tk; 200mg 30tk; 200mg 60tk; 200mg 100tk

Estija - estų - Ravimiamet

medochemie limited - ropinirool - õhukese polümeerikattega tablett - 2mg 42tk; 2mg 126tk; 2mg 21tk; 2mg 210tk; 2mg 84tk

Estija - estų - Ravimiamet

medochemie limited - tsefasoliin - süstelahuse pulber - 1000mg 100tk; 1000mg 10tk; 1000mg 50tk; 1000mg 1tk

Estija - estų - Ravimiamet

medochemie limited - ranitidiin - süste-/infusioonilahus - 25mg 1ml 2ml 100tk; 25mg 1ml 2ml 5tk

Estija - estų - Ravimiamet

medochemie limited - ropinirool - õhukese polümeerikattega tablett - 5mg 42tk; 5mg 210tk; 5mg 84tk; 5mg 21tk; 5mg 126tk

Estija - estų - Ravimiamet

medochemie limited - ropinirool - õhukese polümeerikattega tablett - 1mg 21tk; 1mg 84tk; 1mg 126tk; 1mg 210tk

Estija - estų - Ravimiamet

medochemie limited - atsikloviir - infusioonilahuse pulber - 250mg 1tk; 250mg 10tk; 250mg 5tk

Europos Sąjunga - estų - EMA (European Medicines Agency)

biogen idec ltd - daklüsumab - hulgiskleroos - immunosupressandid - zinbryta on näidustatud täiskasvanud patsientidel hulgiskleroosi retsidiivsete vormide (rms).

Europos Sąjunga - estų - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Estija - estų - Ravimiamet

medochemie iberia s.a. - nefopaam - süste-/infusioonilahus - 20mg 2ml 2ml 10tk; 20mg 2ml 2ml 5tk